The US government's ARPA-H has selected the University of Queensland to help build a nationwide network of hospitals capable of producing personalized RNA medicines on demand. The goal: get patients their treatment within days of diagnosis, not months. Think custom cancer vaccines and rare disease therapies — made right where you're being treated.
The US Advanced Research Projects Agency for Health (ARPA-H) has selected the University of Queensland's BASE mRNA Facility to lead a landmark biomanufacturing initiative. As part of a broader consortium of universities, companies, and research institutes, UQ could receive up to $57 million AUD ($40M USD) to develop technology that enables personalized RNA medicines — like custom cancer vaccines and rare genetic disease treatments — to be manufactured directly in hospitals.
The vision is a nationwide US hospital network where patients receive tailor-made RNA therapies within a week of diagnosis. Currently, these medicines are produced in a small number of large, specialized factories, with patients often waiting months. UQ's role centers on quality control: developing an automated system using nanopore sequencing to verify the safety and accuracy of each RNA medicine before it reaches a patient — replacing what previously required multiple tests with just one.
By the Numbers:
Why it matters: This program could fundamentally reshape how personalized medicines are delivered — moving production from centralized factories to the point of care. For patients with cancer or rare diseases, faster access to custom therapies could be life-changing.
